Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

(S)-MRTX-1719

😃Good
Catalog No. T62960Cas No. 2630904-44-6
Alias (S)-Navlimetostat, (S)-MRTX1719, (S)-BMS-986504, (S)-BMS986504

(S)-MRTX-1719 is the S-enantiomer of Navlimetostat and acts as a PRMT5/MTA complex inhibitor with an IC50 value of 7070 nM, enabling selective modulation of arginine methylation, epigenetic regulation, and transcriptional control, (S)-MRTX-1719 is widely applied in cancer epigenetics research to investigate PRMT5-dependent tumor growth and therapeutic vulnerabilities.

(S)-MRTX-1719

(S)-MRTX-1719

😃Good
Catalog No. T62960Alias (S)-Navlimetostat, (S)-MRTX1719, (S)-BMS-986504, (S)-BMS986504Cas No. 2630904-44-6
(S)-MRTX-1719 is the S-enantiomer of Navlimetostat and acts as a PRMT5/MTA complex inhibitor with an IC50 value of 7070 nM, enabling selective modulation of arginine methylation, epigenetic regulation, and transcriptional control, (S)-MRTX-1719 is widely applied in cancer epigenetics research to investigate PRMT5-dependent tumor growth and therapeutic vulnerabilities.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$99610-14 weeks10-14 weeks
2 mg$1,47010-14 weeks10-14 weeks
5 mg$2,32010-14 weeks10-14 weeks
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
(S)-MRTX-1719 is the S-enantiomer of Navlimetostat and acts as a PRMT5/MTA complex inhibitor with an IC50 value of 7070 nM, enabling selective modulation of arginine methylation, epigenetic regulation, and transcriptional control, (S)-MRTX-1719 is widely applied in cancer epigenetics research to investigate PRMT5-dependent tumor growth and therapeutic vulnerabilities.
In vitro
In MTAP-deleted cancer cells, (S)-MRTX-1719 exhibited MTA-dependent binding to PRMT5 and inhibited the methylation of cellular substrates (specifically SDMA) with an IC50 of < 10 nM [1].
In vivo
In xenograft models such as HCT116 MTAP-/- and LU99, daily oral administration of (S)-MRTX-1719 resulted in tumor regressions. The efficacy correlates with the reduction of SDMA levels in tumor tissue. In contrast to early PRMT5 inhibitors, (S)-MRTX-1719 did not cause bone marrow toxicity at efficacious doses, as normal hematopoietic cells do not accumulate MTA, preventing the inhibition of PRMT5 in these tissues [1].
Synonyms(S)-Navlimetostat, (S)-MRTX1719, (S)-BMS-986504, (S)-BMS986504
Chemical Properties
Molecular Weight464.88
FormulaC23H18ClFN6O2
Cas No.2630904-44-6
SmilesN#CC1=C(OC2CC2)C=C(Cl)C(F)=C1C3=C(C=NN3C)C=4C=CC=5C(=O)NN=C(C5C4)CN
Storage & Solubility Information
StorageIn solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy (S)-MRTX-1719 | purchase (S)-MRTX-1719 | (S)-MRTX-1719 cost | order (S)-MRTX-1719 | (S)-MRTX-1719 chemical structure | (S)-MRTX-1719 in vivo | (S)-MRTX-1719 in vitro | (S)-MRTX-1719 formula | (S)-MRTX-1719 molecular weight